155 related articles for article (PubMed ID: 29104489)
21. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
22. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
23. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
24. Small Peptides as Modulators of Serine Proteases.
Xu P; Huang M
Curr Med Chem; 2020; 27(22):3686-3705. PubMed ID: 30332941
[TBL] [Abstract][Full Text] [Related]
25. The mouse testis is the source of various serine proteases and serine proteinase inhibitors (SERPINs): Serine proteases and SERPINs identified in Leydig cells are under gonadotropin regulation.
Odet F; Verot A; Le Magueresse-Battistoni B
Endocrinology; 2006 Sep; 147(9):4374-83. PubMed ID: 16740973
[TBL] [Abstract][Full Text] [Related]
26. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
Yang SQ; Craik CS
J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
28. Engineering of a macromolecular scaffold to develop specific protease inhibitors.
Stoop AA; Craik CS
Nat Biotechnol; 2003 Sep; 21(9):1063-8. PubMed ID: 12923547
[TBL] [Abstract][Full Text] [Related]
29. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Gladysz R; Adriaenssens Y; De Winter H; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
J Med Chem; 2015 Dec; 58(23):9238-57. PubMed ID: 26575094
[TBL] [Abstract][Full Text] [Related]
30. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
Ellis V; Whawell SA; Werner F; Deadman JJ
Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
[TBL] [Abstract][Full Text] [Related]
31. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
32. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
33. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
34. Highly potent fibrinolytic serine protease from Streptomyces.
Uesugi Y; Usuki H; Iwabuchi M; Hatanaka T
Enzyme Microb Technol; 2011 Jan; 48(1):7-12. PubMed ID: 22112764
[TBL] [Abstract][Full Text] [Related]
35. Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids.
Chen S; Gfeller D; Buth SA; Michielin O; Leiman PG; Heinis C
Chembiochem; 2013 Jul; 14(11):1316-22. PubMed ID: 23828687
[TBL] [Abstract][Full Text] [Related]
36. Phage Display Selected Cyclic Peptide Inhibitors of Kallikrein-Related Peptidases 5 and 7 and Their
Gonschorek P; Zorzi A; Maric T; Le Jeune M; Schüttel M; Montagnon M; Gómez-Ojea R; Vollmar DP; Whitfield C; Reymond L; Carle V; Verma H; Schilling O; Hovnanian A; Heinis C
J Med Chem; 2022 Jul; 65(14):9735-9749. PubMed ID: 35653695
[TBL] [Abstract][Full Text] [Related]
37. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
[TBL] [Abstract][Full Text] [Related]
38. Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases.
Baeriswyl V; Heinis C
Protein Eng Des Sel; 2013 Jan; 26(1):81-9. PubMed ID: 23100545
[TBL] [Abstract][Full Text] [Related]
39. Rezymogenation of active urokinase induced by an inhibitory antibody.
Jiang L; Botkjaer KA; Andersen LM; Yuan C; Andreasen PA; Huang M
Biochem J; 2013 Jan; 449(1):161-6. PubMed ID: 23016918
[TBL] [Abstract][Full Text] [Related]
40. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
